These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9625675)

  • 1. Monitored isoniazid prophylaxis for low-risk tuberculin reactors.
    Moulding T
    Ann Intern Med; 1998 Jun; 128(12 Pt 1):1048. PubMed ID: 9625675
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three basic characteristics of the tuberculin reaction to be observed in the prophylactic treatment of positive reactors.
    Duboczy BO
    Am Rev Respir Dis; 1968 Aug; 98(2):319. PubMed ID: 5667763
    [No Abstract]   [Full Text] [Related]  

  • 4. When should INH prophylaxis be given to a dialysis patient with a positive tuberculin skin test but with a normal CXR?
    Hodowanec AC; Trenholme GM
    Semin Dial; 2011; 24(4):440-1. PubMed ID: 21801219
    [No Abstract]   [Full Text] [Related]  

  • 5. Tuberculin skin test and chemoprophylaxis of tuberculosis.
    Ortona L; Fantoni M
    Rays; 1998; 23(1):218-24. PubMed ID: 9673147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
    Sterling TR; Brehm WT; Moore RD; Chaisson RE
    Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement.
    Nelson LJ; Jereb JA; Castro KG
    Pediatrics; 2004 Oct; 114(4):1084-6. PubMed ID: 15466109
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid prophylaxis in tuberculin reactors.
    Blattner RJ
    J Pediatr; 1968 Jan; 72(1):131-3. PubMed ID: 5634935
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chemoprophylaxis for children exposed to tuberculosis].
    Iwasaki T
    Kekkaku; 1993 Jan; 68(1):1-4. PubMed ID: 8437419
    [No Abstract]   [Full Text] [Related]  

  • 10. [Are microbiological studies necessary before starting tuberculosis chemoprophylaxis?].
    Barrasa Villar JI; Guimbao Bescós J; Gotor Lázaro G; Aspíroz Sancho C
    Med Clin (Barc); 1995 Oct; 105(14):559. PubMed ID: 8523937
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact on USAF tuberculosis detection and control program given a low facility tuberculosis prevalence rate.
    Popper SE; Hebrink ST; Smith DA; Stewart TB
    Mil Med; 1996 Jul; 161(7):432-5. PubMed ID: 8754720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.
    Selwyn PA; Sckell BM; Alcabes P; Friedland GH; Klein RS; Schoenbaum EE
    JAMA; 1992 Jul 22-29; 268(4):504-9. PubMed ID: 1619742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients.
    Rose DN; Schechter CB; Sacks HS
    J Gen Intern Med; 1992; 7(6):589-94. PubMed ID: 1360493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K; Alaei A; Mansouri D
    East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of chemoprophylaxis in children and adolescents with high sensitivity to tuberculin].
    Lebedeva LV
    Probl Tuberk; 1967; 45(4):11-5. PubMed ID: 5629119
    [No Abstract]   [Full Text] [Related]  

  • 16. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
    Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
    Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid-resistant cavitary tuberculosis in a physician following isoniazid prophylaxis.
    Karchmer TB; Phipps JD; Giannetta ET; Farr BM
    Infect Control Hosp Epidemiol; 2002 Oct; 23(10):622-5. PubMed ID: 12400895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the Centers for Disease Control and Prevention. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
    JAMA; 2000 Oct; 284(13):1641-2. PubMed ID: 11041738
    [No Abstract]   [Full Text] [Related]  

  • 19. A tuberculin screening and isoniazid preventive therapy program in an inner-city population.
    Bock NN; Metzger BS; Tapia JR; Blumberg HM
    Am J Respir Crit Care Med; 1999 Jan; 159(1):295-300. PubMed ID: 9872853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In support of bacillus of Calmette and Guérin for healthcare workers.
    Jenney AW; Spelman DW
    Infect Control Hosp Epidemiol; 1998 Mar; 19(3):191-3. PubMed ID: 9552189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.